In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.
The Lantern Project will screen for patients who may be suffering from Gaucher disease, Fabry disease, Pompe disease, MPS I, or ASMD, and offer confirmatory DNA testing.
In PNAS this week: DNA vaccine-based approach for Duchenne muscular dystrophy tested in mice, antimicrobial found in bear saliva, and more.
Stat News reports federal regulators have halted Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy trial.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
In Science this week: gene variant linked to inflammatory bowel disease, and more.
The researchers found that it's not necessary to design individual guide RNAs for each DMD mutation or excise large genomic regions with pairs of guide RNAs.
The Salk Institute-led team developed a system for in vivo activation of endogenous target genes through trans-epigenetic remodeling.
AmCare Genomics said that it has a large network that would enable it to raise awareness about Genomic Vision's test for facioscapulohumeral muscular dystrophy.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.